MedTrace Logo

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - PDE5

NCT05039086 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 13021

Last updated 2025-08-06

Study results available
· View outcomes & findings →

Summary

This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication.

Conditions

Interventions

DRUG

PDE5 inhibitor

PDE5 inhibitors (sildenafil, tadalafil) claim is used as the exposure group.

DRUG

Endothelin Receptor Antagonists

Endothelin receptor antagonists (bosentan, ambrisentan, macitentan) claim is used as the reference group.

Sponsors & Collaborators

  • National Institute on Aging (NIA)

    collaborator NIH

  • Rutgers University

    collaborator OTHER

  • Johns Hopkins University

    collaborator OTHER

  • Brigham and Women's Hospital

    lead OTHER

Principal Investigators

  • Madhav Thambisetty, MD, PhD · National Institute on Aging (NIA)

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-01
Primary Completion
2021-09-30
Completion
2022-10-04
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05039086 on ClinicalTrials.gov